ABSTRACTS

[vc_column_text]Authors have the opportunity to share their latest findings with the international community on an even wider scale due to the online presentation of the congress.

Abstracts accepted for presentation at the IEC will be considered for publication in the ILAE journal, Epilepsia (impact factor 6.040).  Those judged suitable by the editorial team based on novelty and scientific impact will be published in an online supplement to the journal.

 

The abstract review process has been completed and all authors have been notified of the outcome.

All authors of abstracts that have been selected for poster presentation will be sent instructions for uploading them to the virtual platform.

 

Please contact the Secretariat at abstracts@epilepsycongress.org with any queries.[/vc_column_text]

[vc_tta_accordion shape=”square” color=”white” spacing=”10″ c_icon=”chevron” active_section=”100″ collapsible_all=”true”][vc_tta_section title=”ABSTRACT CATEGORIES” tab_id=”categories”]

[vc_column_text]

  • Adult Epileptology
  • Basic Sciences
  • Clinical Neurophysiology
  • Comorbidities
  • Drug Therapy
  • Epidemiology
  • Epilepsy in the Elderly
  • Epilepsy in Resource-restricted Settings
  • Epilepsy Surgery
  • Genetics
  • Neuroimaging
  • Neuropsychology
  • Neurostimulation
  • Paediatric Epileptology
  • Pandemic Response
  • Psychiatry
  • Social Issues/Nursing
  • Status Epilepticus
  • Terminology and Classification
  • Women’s Issues

[/vc_column_text][vc_empty_space height=”16px”]

[vc_icon icon_fontawesome=”fa fa-file-text” color=”white” background_style=”boxed” background_color=”custom” size=”xl” align=”center” css=”.vc_custom_1542100592006{padding-top: 10px !important;}”][vc_column_text]

ABSTRACT CATEGORIES

[/vc_column_text]

[/vc_tta_section][vc_tta_section title=”ABSTRACT GUIDELINES” tab_id=”abstract-guidelines”][vc_column_text]Abstract Submission Rules

1.  Abstracts will not be accepted unless they are submitted online via the online abstract submission system before midnight (GMT) on the deadline date. Abstracts received after this date will NOT be accepted. Abstracts submitted by post, fax or email will NOT be considered.

2.  All abstracts should be written, submitted and presented in English with a maximum word count of 300 words (not including the abstract title, authors and institutions).

3.  Authors will be notified in writing as to whether or not their abstract has been accepted by the Abstract Review Committee. The decision of the committee is final and no correspondence will be entered into.

4.  Once an abstract has been accepted, the presenting author must register for the congress for final acceptance. An abstract presenter may not register as a day delegate.

5.  Abstracts accepted and presented at the congress will be listed on the congress website. Subject to editorial review, abstracts may be published in a supplement to Epilepsia.

6.  The abstracts of authors who do not register for the congress will be excluded from publication.

7.  Instructions for both platform and eposter presentations will be available on the congress website. Authors selected for oral presentations should use Microsoft PowerPoint only (PC format).

8.  All correspondence will be sent to the submitting author only. It is the responsibility of the submitting author to forward any relevant correspondence to the presenting author.

 

Abstract Content Rules

1.  Abstract submitters should ensure that the final version is submitted by the deadline; changes will not be permitted once the deadline has passed.

2.  Institution information should be provided for all authors. Please include institution, city, state/ province and country but exclude department, division, laboratory, etc.

3.  A topic category for each abstract must be selected during the submission process; the abstract topics may be found here.

4.  Abstracts should be structured in 4 sections as follows:

  • Purpose: Should indicate the objectives of the work being presented.
  • Method: Should describe study material or subjects (e.g. number and type of patients), intervention and evaluation procedures.
  • Results: Should summarize the main findings. Wherever possible, give numerical values, including means with SD or SEM, and statistical significance or confidence intervals.
  • Conclusion: Should state briefly the conclusions reached in the work.

5.  Figures, tables and other illustrations may not be included.

6.  If the work was supported by funds provided by a commercial organisation this should be stated in a short acknowledgment at the end of the abstract. Other sources of funding may be acknowledged in the same way.

7.  Submission of multiple abstracts describing different components of the same study is not appropriate. All findings generated from the same study should be included in a single abstract.

8.  Abstracts containing single case reports will not usually be accepted, unless the report is of outstanding scientific or clinical interest because of the uniqueness of the findings or the sophistication of the investigations.

9.  Abstracts containing data considered to be insufficiently informative will not be accepted.

10.  Authors should use a concise title that indicates the content of the abstract. Abbreviations should be avoided in the title.

11.  For intervention studies (for example, therapeutic trials), type of design (prospective or retrospective, controlled or uncontrolled, randomized or observational, open vs. single-blind vs. double-blind), dosages, assessment methods and duration of follow-up should be specified.

12.  Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.

13.  Abbreviations should be used sparingly. For words that are abbreviated, use the whole term the first time, followed by the standard abbreviation in parenthesis.

14.  References should be used sparingly. They should be included within the text in brackets. For journals, mention first author “et al”, followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages (e.g. Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author “et al”, editor, title, publisher, city of publication, year and inclusive pages (e.g. Levy RH et al. In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.).

15.  Submission of an abstract automatically implies acknowledgment that the work described was conducted in accordance with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in rejection of the abstract.[/vc_column_text][/vc_tta_section][vc_tta_section title=”FREQUENTLY ASKED QUESTIONS” tab_id=”faq”]

[vc_text_separator title=”ABSTRACT SUBMISSION”][vc_column_text]How do I submit an abstract?

Abstracts will only be accepted for review if submitted via the congress abstract submission system here. Abstracts will not be accepted for review if received in any other way, e.g. by email.

Can I make changes to my abstract after submission?

You may make changes to your submitted abstract until the official submission deadline.

Once the abstract submission deadline has passed, changes are not permitted unless they relate to the results of the study. In this case only, please contact abstracts@epilepsycongress.org.

Can I submit an abstract after the deadline?

Abstracts will not be accepted for review after the deadline. Please contact abstracts@epilepsycongress.org with any queries.

Can an Encore Abstract be submitted?

Yes an encore abstract may be submitted, provided that there is no copyright issue with the original publisher.

What is the abstract word count?

Maximum word count is 300.[/vc_column_text][vc_text_separator title=”ABSTRACT ACCEPTANCE” css=”.vc_custom_1539086816652{padding-top: 15px !important;}”][vc_column_text]When will I know if my abstract has been accepted?

Authors will be notified of the outcome of the abstract review in April 2021.

How will I receive the information from the Secretariat?

Contact details provided at the time of submission will be used for all correspondence related to the congress. Please ensure that the correct details are entered.

All correspondence will be sent to the submitting author only. It is the responsibility of the submitting author to forward any relevant correspondence to the presenting author, if different, and any co-authors.

How will my abstract be presented at the congress?

Authors of abstracts which have been accepted for presentation will receive all details by email using the contact details provided at the time of submission.

My colleague has received confirmation of their abstract acceptance and I did not, is there something wrong?

Please contact abstracts@epilepsycongress.org.

Will my accepted abstract be published?

Abstracts accepted for presentation at the IEC will be considered for publication in Epilepsia.  Those judged suitable by the editorial team based on novelty and scientific impact will be published electronically. Others may be accepted for presentation at the meeting but will not be published.[/vc_column_text][vc_text_separator title=”ABSTRACTS – GENERAL QUERIES”][vc_column_text]Which reference number should I use when I send a query to the Secretariat?

The personal ID Reference Number that you received when you submitted your abstract should be mentioned in all correspondence.

I am not the first author; may I present the poster on behalf of my colleagues?

Presentation by a second author may be allowed. Once your registration has been completed, please contact abstracts@epilepsycongress.org. Please note however that each author is permitted to present only once during the congress (not including invited lectures).

Can the presenting author pay one-day registration fee (for the day when the poster is displayed)?

No. Once an abstract has been approved, the presenting author must register for the entire congress for final acceptance. An abstract presenter may not register as a day delegate. Non-registered authors may be excluded from publication.

I am an invited speaker in the congress programme; do I need to submit an abstract?

Invited speakers are not required to submit abstracts to illustrate their talks.

I have been selected for a platform session but I would have preferred a poster presentation, what can I do?

During the abstract submission process you were asked if you would prefer poster or oral (platform) presentation, or if you do not have a preference.

The Abstract Review Committee (ARC) took this preference into account and did not select an abstract for platform presentation if the submitter indicated that s/he does not want a platform presentation.

However, if you indicated that you had no preference between poster and platform presentation, then the ARC has selected your work to be presented in a platform session because they felt that it was of high quality and that a large audience would be interested in knowing more about the study. It would be a shame not to use this opportunity to present your work! However if you are unable to make an oral presentation please contact the secretariat at abstracts@epilepsycongress.org for alternative arrangements.

How do I find information about eposters?

All information relating to eposters will be available on the website after the abstract review is completed.[/vc_column_text][vc_empty_space height=”16px”]

[vc_icon icon_fontawesome=”fa fa-question-circle” color=”white” background_style=”boxed” background_color=”custom” size=”xl” align=”center” css=”.vc_custom_1542100754807{padding-top: 10px !important;}”][vc_column_text]

FREQUENTLY ASKED QUESTIONS

[/vc_column_text]

[/vc_tta_section][vc_tta_section title=”EMBARGO POLICY” tab_id=”embargo”][vc_column_text]The embargo on all abstracts will be lifted officially on Friday, 27 August 2021, 18.00 UTC+1. The embargo policy prohibits the publication of the contents of abstracts before the embargo date and time.[/vc_column_text][/vc_tta_section][vc_tta_section title=”ABSTRACT REVIEW COMMITTEE – ACKNOWLEDGEMENT” tab_id=”abstract-review-committee”][vc_column_text]The Scientific and Organising Committee would like to extend its gratitude for the assistance of the following people with the review of the abstracts.

Amza Ali (Jamaica)
Stéphane Auvin (France)
Fabrice Bartolomei (France)
Stéphanie Baulac (France)
Andrea Bernasconi (Canada)
Meir Bialer (Israel)
Alicia Bogacz (Uruguay)
Martin Brodie (Scotland)
Lorenzo Caciagli (USA)
Fernando Cendes (Brazil)
Yotin Chinavarun (Thailand)
Mark Cook (Australia)
J Helen Cross (United Kingdom)
Marco de Curtis (Italy)
Norman Delanty (Ireland)
Kirsty Donald (South Africa)
Divyanshu Dubey (USA)
Paolo Federico (Canada)
Birgit Frauscher (Canada)
Jacqueline French (USA)
Aristea Galanopoulou (USA)
Marian Galovic (Switzerland)
Elena Gardella (Denmark)
Tiziana Granata (Italy)
Alla Guekht (Russian Federation)
Christoph Helmstädter (Germany)
Oliver Henning (Norway)
Akio Ikeda (Japan)
Julia Jacobs (Canada)
Michael Kerr (United Kingdom)
Shih Hui Lim (Singapore)
Iscia Lopes Cendes (Brazil)
Aileen McGonigal (France)
Rosa Michaelis (Germany)
Rima Nabbout (France)
Caroline Neuray (United Kingdom)
Terence O’Brien (Australia)
Natela Okujava (Georgia)
Archana Patel (USA)
Emilio Perucca (Italy)
Marielle Prevos-Morgant (Switzerland)
Stefan Rampp (Germany)
Genevieve Rayner (Australia)
Markus Reuber (United Kingdom)
Guido Rubboli (Denmark)
Cristina Ruedell Reschke (Ireland)
Philippe Ryvlin (Switzerland)
Mary Secco (Canada)
Margitta Seeck (Switzerland)
Graeme Shears (Australia)
Mary Lou Smith (Canada)
Francesca Sofia (Italy)
Nicola Specchio (Italy)
Michael Sperling (USA)
Torbjörn Tomson (Sweden)
Eugen Trinka (Austria)
Kette Valente (Brazil)
Samuel Wiebe (Canada)
Jo Wilmshurst (South Africa)
Sarah Wilson (Australia)
Elaine Wirrell (USA)

[/vc_column_text][/vc_tta_section][/vc_tta_accordion]